Abstract
Background: Thioredoxin (Trx) and lactoferrin (Lf) are multifunctional proteins part of the body anti-oxidant defence and counteract the oxidative tissue damage. The purpose of our study is to investigate Trx and Lf levels in serum of rheumatoid arthritis (RA) patients and establish the association of these proteins with the rheumatoid factor (RF) and other disease markers.
Methods: The study included 114 patients with RA and 42 healthy subjects. Serum concentrations of Trx, Lf, RF, anti-cyclic citrullinated peptide (anti-CCP) antibodies, CRP, and IL-6 were determined using commercially available ELISA kits.
Results: Serum thioredoxin levels in RA were significantly higher compared to the control group, 36.4 (29.6-40.2), ng/mL versus 19.0 (16.3-26.8), ng/mL, p < 0.0001. Serum lactoferrin levels were elevated in RA compared to the control group but the difference was not statistically significant, 579.6 (312.8-947.5), ng/mL versus 519.0 (262.5-928.0), ng/mL. We found significant negative correlations of Trx and Lf with rheumatoid factor in RA (r= -0.254, p=0.05 and r= -0.238, p=0.014, respectively). The correlations of thioredoxin and lactoferrin with other disease markers such as anti-CCP antibodies, DAS28, ESR, CRP, and IL-6 were not statistically significant. A strong positive correlation between Trx and Lf was observed in the study group of RA patients (r=0.519, p<0.0001), but not in the control group.
Conclusions: Thioredoxin and lactoferrin were associated with rheumatoid factor, but not with anti-CCP antibodies and systemic disease activity, therefore the two proteins may serve as new biomarkers for assessment of pathological changes and monitoring of disease severity and progression in RA.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.